DIOIC BIOLOGICS

The graphical representation shows an R squared value of 0.0013 for Saniprazole mkII and 0.00 for Saniprazole, highlighting the time period it takes for remission to occur in the use and cessation use of Saniprazole and Saniprazole mkII, with Saniprazole mkII geared to treatment of EoE on extended duration of remission symptoms.

Confirmation to the FDA CDER next gen portal for Emepi-CMP001, Saniprazole, Saniprazole mkII and Emepi- CMP001 Intravenous for INDs NDAs on Orphan status in reciept of an Acknolodgement letter to request applications.

Made submissions to the FDA CDER next gen portal for Emepi-CMP001, Saniprazole, Saniprazole mkII and Emepi- CMP001 Intravenous for INDs NDAs on addendum and request numbers 00281366, 00281365, 00281363.

Made submissions to the FDA CDER next gen portal for Emepi-CMP001, Saniprazole, Saniprazole mkII and Emepi- CMP001 Intravenous

Made inquiry and submitted documentations for a pre-qualification of medicine status.

Current developments with DIOIC Biologics is in contact with NAFDAC (National Agency for Food and Drug Administration and Control) for requests to drug approvals of DRUGS with conducted trials and studies.

Provided updates to DIOIC Biologics with BfArm, the drug regulatory body of Germany for Saniprazole, Saniprazole mkII and Emepi towards regulatory approvals and review in furnishing updates to study datas and trial documentations for Saniprazole, Saniprazole mkII and Emepi.

Made contact with Drug and health product review and approval for Emepi, Saniprazole and Saniprazole mkII for Extraordinary Use New Drug Submission (EUNDS), New Drug Submission (NDS) and an application for a Drug Identification Number for a pharmaceutical product, including non-prescription products attesting to a Labelling Standard (DINA) for division 1 drugs.

DIO Industries Corporporation is currently in negotiation in provision of an offer for Acquisition of FogHorn Therapeutics Inc [FHTX] and have made contact in regards towards a full acquisition of FogHorn Therapeutics INC . 20th of December 2024.

In request from the Veterans Affairs [VA] to purchase 3,900,156 Emepi pill tablets and 757,714.29 Emepi Syringe Fluid of 0.2 - 0.3ml Emepi fluid containers.

Filled and Submitted an IND and NDA with the FDA with the DIOIC's Contact with the FDA.

DIO Industries Corp Biologics submitted applications for drug candidates Saniprazole and Saniprazole mkII for a fast track approval on the 16th of August 2024, with all pertinent information provided to. In submittal for IND and NDA approval submissions was a concurrent study on Anagelsic effects on a patient on a Gastrointestinal medication grant request which was also turned in on the 24th of September 2024. With Study/Trial conclusions to Saniprazole, Saniprazole mkII and Analgesic study of a Gastreointestinal medication also submitted officially on the 31st of October 2024. In business related association to DIOIC, an official bid was turned in for Kimia Farma, Indonesia and BioAmerica for Acquisitions.

DIO Industries Corporporation is currently in discussion with the Indonesian Government in a partial Acquisition of Kimia Farma and have made contact in regards, towards a partial controlling acquisition of Kimia Farma. 17th of September 2024.

DIO Industries Corporporation is currently in a preminilary Interest in Acquisition of BioAmerica Incorporated and have made contact in regards, towards a full acquisition of BioAmerica Incorporated. 12th of September 2024.

DIO Industries Corp is currently undergoing a 7 - Day Remission surrorogate study, i.e a continous evaluation of Saniprazole in cessation usage to determine remission probability subjected to a time frame. This study commmenced on the 25th of January 2024. Conclusive result to the 7-Day study ending on Day 143, Wednesday January 31st, 2024 of the Surrogate study exhibited a zero[0 - 1] scale rating for normalcy suggesting a zero percent [0%] remission investigation and a reaction of inducive coughs with a rating of three [3] of a scaled [(0-1) of 5] with two [2] occurrences in the 7-day concurrent trial, suggesting a [28.6%] reactionary exhibition off Saniprazole on the 7-day study. Primary endpoint interpretation shows zero remissions to symptoms associated to Gastrointestinal conditions like EoE and Gerd and secondary endpoint of reactions in coughs at [28.6%].

Surrogate Study Data on predominant condition in Eoe and Severe Gerd in relation to Emesis.

Data shows a graphical representation os Saniprazole use in a surrogate study of 174 days starting on the 12th of September 2023 to March 4th 2024. attribution to emesis during the period is 3 occurences of 3 plus or minus meals a day with variable dosage utilization attributing to 0.356 for less than 3 or more meals a day and 1.068 of a day representation regardless of meals. In representation, that is 1 for normal and 5 for severity, is 1/1.068 * (100) resulting in a 94% effectiveness of Saniprazole.